Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

Treating PAH patient-derived blood vessel cells with calcitriol reduced vitamin D receptor deficiency and suppressed their ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

The Mini Nutritional Assessment was viable for assessing nutritional status and predicting mortality outcomes in patients ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

Blood levels of two markers may help predict treatment response and outcomes in pulmonary arterial hypertension patients, per ...

The AIIMS Bhopal has achieved a significant milestone by successfully performing a rare and complex surgery to treat a 27-year-old patient diagnosed with Chronic Thromboembolic Pulmonary Artery ...

A recent systematic review assessed the psychometric properties of various instruments for measuring QOL in patients with ...

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension ...